儿童和青少年四价与四价流感疫苗免疫原性和安全性的比较
本Meta分析检索至2019年2月12日的随机临床试验,比较儿童和青少年四价灭活流感疫苗(QIV)与三价灭活流感疫苗(TIV)的免疫原性和安全性。结果显示QIV对共同成分的免疫原性与TIV相似,但对独有B系免疫原性更高;安全性方面仅疼痛报告更多,RR为1.09(95%CI:1.02-1.17)。
要点
- 6月龄至3岁组,QIV对B系(Yamagata)的血清保护率高于TIV-B/Yamagata,合并RR为3.07(95%CI:2.58-3.66)。
- 3岁至18岁组,QIV对Yamagata系的血清阳转率和血清保护率均高于TIV-B/Victoria,合并RR分别为2.30(95%CI:1.83-2.88)和1.16(95%CI:1.03-1.30)。
- 与TIV-B/Yamagata相比,QIV对Victoria系的血清阳转率和血清保护率更高,RR分别为3.09(95%CI:1.99-4.78)和1.72(95%CI:1.22-2.41)。
核心结论
- QIV对共同成分的免疫原性与TIV相似,但对独有B系免疫原性显著更高。
- QIV与TIV具有同样可靠的安全性。
研究设计与样本
- Meta分析,检索PubMed、EMBASE和Cochrane Library截至2019年2月12日发表的随机临床试验。
- 纳入比较儿童和青少年QIV与TIV免疫原性和安全性的随机临床试验。
- 采用随机效应模型进行合并分析。
主要发现
- 6月龄至3岁组,QIV对B系(Yamagata)的血清保护率高于TIV-B/Yamagata,合并RR为3.07(95%CI:2.58-3.66);对另一B系的合并RR为1.06(95%CI:1.01-1.11)。
- 3岁至18岁组,QIV对Yamagata系的血清阳转率和血清保护率高于TIV-B/Victoria,合并RR分别为2.30(95%CI:1.83-2.88)和1.16(95%CI:1.03-1.30)。
- 与TIV-B/Yamagata相比,QIV对Victoria系的血清阳转率和血清保护率更高,RR分别为3.09(95%CI:1.99-4.78)和1.72(95%CI:1.22-2.41)。
- 不良事件方面,仅疼痛在QIV中报告更频繁,RR为1.09(95%CI:1.02-1.17)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children and adolescents are susceptible to influenza. Vaccination is the most important strategy for preventing influenza, yet there are few studies on the immunogenicity and safety of quadrivalent inactivated influenza vaccine (QIV) containing two A strains (H1N1 and H3N2) and two B lineages (Victoria and Yamagata). Therefore, to further clarify the immunogenicity and safety of QIV in children and adolescents, a meta-analysis was performed to provide a reference for the development of influenza prevention strategies. METHODS: PubMed, EMBASE and Cochrane Library were searched for articles published as of February 12, 2019. Random clinical trials comparing the immunogenicity and safety of QIV and TIV among children and adolescents were selected. The main outcomes were comparisons of immunogenicity (seroprotection rate [SPR] and seroconversion rate [SCR] and adverse events using risk ratios (RRs). The meta-analysis was performed using random-effects models. RESULTS: Among the 6 months up to 3 years group, QIV showed a higher SPR for B lineages than for TIV-B/Yamagata, with pooled RRs of 3.07 (95% CI: 2.58-3.66) and 1.06 (95% CI: 1.01-1.11), respectively. For the 3 years through 18 years, QIV had a higher SCR and SPR for the Yamagata lineage than for TIV-B/Victoria, with pooled RRs of 2.30 (95% CI: 1.83-2.88) and 1.16 (95% CI: 1.03-1.30), respectively. Compared to TIV-B/Yamagata, a higher SCR and SPR for the Victoria lineage was found for QIV, with RRs of 3.09 (95% CI: 1.99-4.78) and 1.72 (95% CI: 1.22-2.41), respectively. Regarding adverse events, only pain was more frequently reported for QIV than TIV ; the RR was 1.09 (95% CI: 1.02-1.17). CONCLUSIONS: The immunogenicity of QIV for common ingredients was similar to that of TIV, but the former exhibited significantly higher immunogenicity for the unique lineage. QIV also had the same reliable safety as TIV.
引用
- Huang C, Fu X, Zhou Y, et al. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Vaccine. 2020. PMID: 31948819. doi:10.1016/j.vaccine.2019.11.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。